Michael C Van Zandt

This inventor holds 44 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 12 EPO patents, primarily in Arginase Inhibitors. Top assignees: The Institute for Pharmaceutical Discovery, LLC, Mars, Incorporated, Calithera Biosciences, Inc.. Active years: 2001-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael C Van Zandt. Retrieved from https://idiyas.com/inventor/michael-c-van-zandt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44 (Patent Applications = 5)

% Patents Active = 54.5

CIPO Patents = 1 (Patent Applications = 16)

EPO Patents = 12 (Patent Applications = 10)

Average Co-Inventor Count = 3.2

ph-index = 11

Forward Citations = 265(Granted Patents)

Location History:

Branford, CT (US) (2015)
McLean, VA (US) (2015 - 2018)
Guilford, CT (US) (2001 - 2024)

Company Filing History:

13 out of 16

The Institute for Pharmaceutical Discovery, LLC

Calithera Biosciences, Inc.

patents

4. 5 out of 14

Thetis Pharmaceuticals LLC

patents

5. 3 out of 3

The Institutes for Pharmaceutical Discovery LLC

Alinea Pharmaceuticals, Inc.

patent

8. 1 out of 1

Precision Pharmaceuticals, Inc.

patent

9. 1 out of 834,570

Other

patents

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Arginase Inhibitors

RNA Inhibition

Pro-Resolving Mediators

Therapeutics

Carboxylic Acids

Pyrrolidine Derivatives

Heterocyclic Compounds

Indolealkanoic Acids

Amino Carboxylic Acids

Salts

Phenoxyacetic Acids

Analog Compounds

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421257 - Compositions and methods for inhibiting group II intron RNA (2025-09-23),

2. 12054501 - Compositions and methods for inhibiting arginase activity (2024-08-06),

3. 11925688 - Compositions and methods relating to salts of specialized pro-resolving mediators (2024-03-12),

4. 11739104 - Compositions and methods for inhibiting group II intron RNA (2023-08-29),

5. 11389464 - Arginase inhibitors as therapeutics (2022-07-19),

6. 11370754 - Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide (2022-06-28),

7. 11191840 - Compositions and methods relating to salts of specialized pro-resolving mediators (2021-12-07),

8. 11135298 - Compositions and methods relating to salts of specialized pro-resolving mediators (2021-10-05),

9. 11021495 - Compositions and methods for inhibiting arginase activity (2021-06-01),

10. 10906872 - Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide (2021-02-02),

11. 10851118 - Compositions and methods for inhibiting arginase activity (2020-12-01),

12. 10844080 - Compositions and methods for inhibiting arginase activity (2020-11-24),

13. 10603330 - Arginase inhibitors as therapeutics (2020-03-31),

14. 10597411 - Compositions and methods for inhibiting arginase activity (2020-03-24),

15. 10538537 - Inhibitors of arginase and their therapeutic applications (2020-01-21),

Title: Innovator Spotlight: Michael C Van Zandt - Pioneering Solutions in Guilford, CT

Introduction: Meet Michael C Van Zandt, a prolific inventor based in Guilford, CT, with an impressive portfolio of 42 patents. His groundbreaking work spans diverse fields, revolutionizing the landscape of specialized pro-resolving mediators and group II intron RNA.

Latest Patents: Van Zandt's latest patents showcase his ingenuity and dedication to advancing healthcare and biotechnology. "Compositions and methods relating to salts of specialized pro-resolving mediators" introduce novel compounds to combat chronic inflammation, while "Compositions and methods for inhibiting group II intron RNA" highlight his efforts in disrupting intron splicing for therapeutic purposes.

Career Highlights: With a rich background in innovation, Van Zandt has contributed significantly to The Institute for Pharmaceutical Discovery, LLC, and Mars, Incorporated. Through his inventive spirit, he has solidified his position as a trailblazer in the pharmaceutical and food industries, driving forward cutting-edge solutions.

Collaborations: Collaboration is key in catalyzing transformative change, and Van Zandt has worked alongside top-tier professionals in his field. Notable colleagues include Darren Whitehouse and Gunnar Erik Jagdmann, Jr., who have been instrumental in realizing Van Zandt's visionary projects.

Conclusion: Michael C Van Zandt's exceptional work ethic and pioneering mindset have propelled him to the forefront of innovation in Guilford, CT. His relentless pursuit of excellence and unwavering commitment to crafting groundbreaking solutions continue to inspire and shape the future of biotechnology and healthcare.

Profile summary based on public USPTO records.